Integra Lifesciences Holdings Corp filed its 10-Q with the SEC, and its figures are now in our data. Revenue over the twelve months to Q3 2026 was $1.7 billion, a 0.8% increase on the year before. That growth rate was down 0.8 percentage points from the quarter earlier.
Profitability
The business is profitable. The trailing gross margin stood at 52.4%, while the trailing operating margin reached 4.4%, up 33.7 percentage points from a year earlier. Meanwhile, the trailing net margin was 0.8%. Net income over the twelve months totaled $13.0 million, rising 98.6% on the year before.
The cash picture
Operating cash flow over the twelve months reached $140.4 million, up 57.2% on the year before. Capital spending was $54.6 million, equivalent to 3.3% of revenue. Consequently, free cash flow, operating cash flow less capital spending, stood at $85.8 million. This represented a free-cash-flow margin of 5.2%, up 5.5 percentage points from a year earlier.
The share base
The average diluted share count rose 1.3% over the year.
Against its own history
Set against the company’s own record, today’s free-cash-flow margin of 5.2% is higher than 28% of past quarterly readings, which have ranged from −2.3% to 19.3%. Today’s operating margin of 4.4% exceeds 28% of past readings (−30.9% to 15.3%). Additionally, today’s twelve-month revenue growth rate of 0.8% is higher than 26% of past readings (−9.6% to 35.6%).
What it means for value
For valuation, the figures matter through our model. In our model, a 5 percentage point decrease in growth would lower the value by 29.5%, while a 5 percentage point increase would raise it by 38.8%. A 1 percentage point reduction in free-cash-flow margin would lower the value by 12.2%.
What to watch
The next filing will show whether the trends above continue, slow or reverse.
